IGI Logo

Biocon is currently trading at Rs. 390.25, up by 5.20 points or 1.35% from its previous closing of Rs. 385.05 on the BSE.

The scrip opened at Rs. 390.55 and has touched a high and low of Rs. 392.50 and Rs. 387.70 respectively. So far 25848 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.

Last one week high and low of the scrip stood at Rs. 398.85 and Rs. 383.10 respectively. The current market cap of the company is Rs. 58580.17 crore.

The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.71% and 16.83% respectively.

Biocon’s subsidiary -- Biocon Biologics is all set to introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

The company is set to unveil three new biosimilar oncology assets -- Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo), and Pembrolizumab (Keytruda) --at the 2026 J.P. Morgan Healthcare Conference. With these new oncology assets, including two PD-1 inhibitors, Biocon Biologics will have one of the most comprehensive oncology portfolios in the industry. This will enable the company to broaden the availability of critical oncology therapies through cost?effective biosimilar alternatives.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.